Browsing Cancer Biology by author "Kramer-Marek, Gabriela"
Now showing items 1-6 of 6
-
Affibody-Based PET Imaging to Guide EGFR-Targeted Cancer Therapy in Head and Neck Squamous Cell Cancer Models.
Burley, TA; Da Pieve, C; Martins, CD; Ciobota, DM; Allott, L; et al. (SOC NUCLEAR MEDICINE INC, 2019-03-01)In head and neck squamous cell cancer, the human epidermal growth factor receptor 1 (EGFR) is the dominant signaling molecule among all members of the family. So far, cetuximab is the only approved anti-EGFR monoclonal ... -
HER3-Mediated Resistance to Hsp90 Inhibition Detected in Breast Cancer Xenografts by Affibody-Based PET Imaging.
Martins, CD; Da Pieve, C; Burley, TA; Smith, R; Ciobota, DM; et al. (AMER ASSOC CANCER RESEARCH, 2018-04-15)Purpose: Recent studies have highlighted a role of HER3 in HER2-driven cancers (e.g., breast cancer), implicating the upregulation of the receptor in resistance to HER-targeted therapies and Hsp90 inhibitors (e.g., AUY922). ... -
Immunomodulatory activity of IR700-labelled affibody targeting HER2.
Mączyńska, J; Da Pieve, C; Burley, TA; Raes, F; Shah, A; et al. (SPRINGERNATURE, 2020-10-20)There is an urgent need to develop therapeutic approaches that can increase the response rate to immuno-oncology agents. Photoimmunotherapy has recently been shown to generate anti-tumour immunological responses by releasing ... -
Near-infrared photoimmunotherapy targeting EGFR-Shedding new light on glioblastoma treatment.
Burley, TA; Mączyńska, J; Shah, A; Szopa, W; Harrington, KJ; et al. (WILEY, 2018-06-01)Glioblastomas (GBMs) are high-grade brain tumors, differentially driven by alterations (amplification, deletion or missense mutations) in the epidermal growth factor receptor (EGFR), that carry a poor prognosis of just ... -
Oncolytic vaccinia virus as a vector for therapeutic sodium iodide symporter gene therapy in prostate cancer.
Mansfield, DC; Kyula, JN; Rosenfelder, N; Chao-Chu, J; Kramer-Marek, G; et al. (NATURE PUBLISHING GROUP, 2016-04-01)Oncolytic strains of vaccinia virus are currently in clinical development with clear evidence of safety and promising signs of efficacy. Addition of therapeutic genes to the viral genome may increase the therapeutic efficacy ... -
Triggering anti-GBM immune response with EGFR-mediated photoimmunotherapy.
Mączyńska, J; Raes, F; Da Pieve, C; Turnock, S; Boult, JKR; et al. (BMC, 2022-01-21)BACKGROUND: Surgical resection followed by chemo-radiation postpones glioblastoma (GBM) progression and extends patient survival, but these tumours eventually recur. Multimodal treatment plans combining intraoperative ...